Patents
Broad patent granted for use of immune stimulatory CpG oligonucleotides
Published in Hepatitis Weekly, December 22nd, 2003
The patent broadly protects the use of immune stimulatory CpG oligonucleotides (CpG TLR9 agonists) to treat or prevent cancer or to enhance multimodal cancer treatment regimens.
The patent covers a family of synthetic oligonucleotides that contain CpG motifs. Cancer treatment applications protected by this patent include CpG TLR9 agonist monotherapy and combination therapies where CpG TLR9 agonists are used to enhance the anticancer activity of other regimens,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-12-22)
More Articles from Hepatitis Weekly
- Osteoporosis
Liver transplant candidates should be screened for osteopenia - Transplantation
Adefovir offers rescue after hepatitis B virus reinfections of liver grafts - Chronic Hepatitis C
End of treatment responses with HCV induction and standard regimens are similar - Fibrosis
Hepatitis C virus proteins are not direct precursors of fibrogenic events - Oncology
Alpha-fetoprotein mRNA does not predict liver cancer in cirrhosis patients - Transplantation
Antivirals stem HCV recurrence when issued shortly after liver transplantation - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
